Lixisenatide
Lixisenatide, a peptide. Exenatide backbone with a 6-lysine C-terminal extension (and Pro replacement at position 38). Short plasma t½ (~3 h) produces predominantly…
Exenatide backbone with a 6-lysine C-terminal extension (and Pro replacement at position 38). Short plasma t½ (~3 h) produces predominantly prandial GLP-1R exposure → strong postprandial glycaemic effect mostly through slowed gastric emptying. Less sustained basal effect than weekly GLP-1 agonists; ELIXA trial was CV-neutral.
Sources: PMID:28133970